OKYO Pharma (NASDAQ:OKYO) Issues Earnings Results

OKYO Pharma (NASDAQ:OKYO) issued its quarterly earnings data on Friday. The company reported ($2.28) earnings per share for the quarter, FiscalAI reports.

OKYO Pharma Trading Up 0.5%

Shares of OKYO stock opened at $2.05 on Friday. OKYO Pharma has a 12 month low of $1.01 and a 12 month high of $3.35. The stock has a 50-day moving average price of $2.13 and a 200 day moving average price of $2.32.

Institutional Investors Weigh In On OKYO Pharma

An institutional investor recently bought a new position in OKYO Pharma stock. Citadel Advisors LLC acquired a new stake in OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 15,355 shares of the company’s stock, valued at approximately $31,000. Hedge funds and other institutional investors own 2.97% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of OKYO Pharma in a research report on Thursday, January 22nd. HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of OKYO Pharma in a report on Thursday. Finally, B. Riley began coverage on OKYO Pharma in a report on Monday, December 8th. They issued a “buy” rating and a $5.00 price target for the company. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $6.00.

About OKYO Pharma

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.